Immutep Ltd logo

Immutep Ltd

ASX:IMM (Australia)  
A$ 0.45 (+16.88%) Apr 24
At Loss
P/B:
3.97
Market Cap:
A$ 534.98M ($ 347.78M)
Enterprise V:
A$ 432.86M ($ 281.39M)
Volume:
13.37M
Avg Vol (2M):
1.68M
Also Trade In:
Volume:
13.37M
At Loss
Avg Vol (2M):
1.68M

Business Description

Description
Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trails, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia and derives the majority of the revenue from the sale of the products.
Name Current Vs Industry Vs History
Cash-To-Debt 64.23
Equity-to-Asset 0.93
Debt-to-Equity 0.01
Debt-to-EBITDA N/A
N/A
N/A
Interest Coverage N/A
N/A
N/A
Piotroski F-Score 1/9
0
1
2
3
4
5
6
7
8
9
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 89.15
9-Day RSI 78.57
14-Day RSI 71.46
6-1 Month Momentum % 20.31
12-1 Month Momentum % 53.36

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 17.24
Quick Ratio 17.24
Cash Ratio 15.82

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -33.8
Shareholder Yield % -0.02

Financials (Next Earnings Date:2024-04-26 Est.)

ASX:IMM's 30-Y Financials
Income Statement Breakdown
No Enough Data
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
No Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015

Immutep Ltd Executives

Details

GF Value

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil A$)
EPS (TTM) (A$) -0.045
Beta 2.26
Volatility % 26.5
14-Day RSI 71.46
14-Day ATR (A$) 0.019584
20-Day SMA (A$) 0.3815
12-1 Month Momentum % 53.36
52-Week Range (A$) 0.221511 - 0.455
Shares Outstanding (Mil) 1,188.83

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 1
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Immutep Ltd Filings

Filing Date Document Date Form
No Filing Data

Immutep Ltd Stock Events

Financials Calendars
Event Date Price(A$)
No Event Data

Immutep Ltd Frequently Asked Questions

What is Immutep Ltd(ASX:IMM)'s stock price today?
The current price of ASX:IMM is A$0.45. The 52 week high of ASX:IMM is A$0.46 and 52 week low is A$0.22.
When is next earnings date of Immutep Ltd(ASX:IMM)?
The next earnings date of Immutep Ltd(ASX:IMM) is 2024-04-26 Est..
Does Immutep Ltd(ASX:IMM) pay dividends? If so, how much?
Immutep Ltd(ASX:IMM) does not pay dividend.

Press Release

Subject Date
No Press Release